Cited by 192Systemic Lupus Erythematosus ResearchAdrenal Hormones and DisordersSystemic Sclerosis and Related Diseases

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Dehydroepiandrosterone in systemic lupus erythematosus

Van Vollenhoven, Ronald F., Engleman, Edgar G., Mcguire, James L.·1995·Arthritis & Rheumatism

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine if dehydroepiandrosterone (DHEA) is beneficial in the treatment of systemic lupus erythematosus (SLE). METHODS: In a double-blind, placebo-controlled, randomized trial, 28 female patients with mild to moderate SLE were given DHEA 200 mg/day or placebo for 3 months. Outcomes included the SLE Disease Activity Index (SLEDAI) score, patient's and physician's overall assessments of disease activity, and concurrent corticosteroid dosages (which were adjusted as clinically indicated). RESULTS: In the patients who were receiving DHEA, the SLEDAI score, patient's and physician's overall assessment of disease activity, and concurrent prednisone dosage decreased, while in the patients taking placebo, small increases were seen. The difference in patient's assessment between the groups was statistically significant (P = 0.022, adjusted). Lupus flares occurred more frequently in the placebo group (P = 0.053). Mild acne was a frequent side effect of DHEA. CONCLUSION: DHEA may be useful as a therapeutic agent for the treatment of mild to moderate SLE. Further studies of DHEA in the treatment of SLE are warranted.

Integrity signals

Registry

Crossref · 10.1002/art.1780381216

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).
Linker‐Israeli, M., Bakke, A. C., Kitridou, R. C., Gendler, S. J., Gillis, S. A., & Horwitz, D. A. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.6.2651 · Cited by 453
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.
Alcocer-Varela, J. C., & Alarcón-Segovia, D. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110579 · Cited by 422
Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.
NESTLER, J. E., BARLASCINI, C. O., CLORE, J. N., & BLACKARD, W. G. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-1-57 · Cited by 414
Frequency of lupus flare in pregnancy: The hopkins lupus pregnancy center experience
Petri, M., Howard, D., & Repke, J. T. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780341210 · Cited by 392
Physiological importance of dehydroepiandrosterone.
Eberling, P., & Koivisto, V. A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92587-9 · Cited by 365
An Investigation of the Cause of the Eosinophilia–Myalgia Syndrome Associated with Tryptophan Use
Belongia, E. A., Hedberg, C. W., Gleich, G. J., White, K. E., Mayeno, A. N., Loegering, D. A., Dunnette, S. L., Pirie, P. L., MacDonald, K. L., & Osterholm, M. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008093230601 · Cited by 356
Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function.
Daynes, R. A., Araneo, B. A., Dowell, T., Huang, K. L., & Dudley, D. J. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.4.979 · Cited by 341
Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice.
Steinberg, A. D., Roths, J. B., Murphy, E. D., Steinberg, R. T., & Raveche, E. S. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.871 · Cited by 326

Flagged first, then by citations

Show all 36 references

1 of the 36 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Felt V, 1966, Metabolic effects of DHEA and atromid in patients with hyperlipaemia, Cor Vasa, 8, 40

Sorted by citations

Items 101–192 of 192

DHEA supplementation: the claims in perspective.
Olech, E., & Merrill, J. (2005) · Cleveland Clinic journal of medicine · doi:10.3949/ccjm.72.11.965 · Cited by 25
Administration of Dehydroepiandrosterone Sulfate Retards Onset but not Progression of Autoimmune Disease in NZB/W Mice
Norton, S. D., Harrison, L. L., Yowell, R. L., & Araneo, B. A. (1997) · Autoimmunity · doi:10.3109/08916939708994738 · Cited by 20
Emerging Concepts for Sexual Predilection in the Disease Systemic Lupus Erythematosus
Lahita, R. G. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07623.x · Cited by 19
Therapy of systemic lupus erythematosus: new agents and new evidence
Ruiz‐Irastorza, G., Khamashta, M. A., & Hughes, G. R. V. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1581 · Cited by 18
Mechanisms of lupus: the role of estrogens.
Rl, Y. (1999) · PubMed · Cited by 18
DHEA and Sport
Corrigan, B. (2002) · Clinical Journal of Sport Medicine · doi:10.1097/00042752-200207000-00006 · Cited by 17
Transformations of DHEA and its metabolites by rat liver
Lardy, H. A., Marwah, A. K., & Marwah, P. (2002) · Lipids · doi:10.1007/s11745-002-1019-7 · Cited by 17
Estrogen receptor alpha deficiency protects against development of cognitive impairment in murine lupus
Cunningham, M. A., Wirth, J. R., Freeman, L. R., Boger, H. A., Granholm, A., & Gilkeson, G. S. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0171-x · Cited by 16
DHEA: panacea or snake oil?
Sirrs, S. M., & Bebb, R. A. (1999) · PubMed Central · Cited by 16
Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled trial
Poretsky, L., Brillon, D. J., Ferrando, S. J., Chiu, J. A., McElhiney, M. C., Ferenczi, A., Sison, M. C. I. P., Haller, I., & Rabkin, J. G. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.013 · Cited by 15
Androgen therapy in non-gonadal disease
Liu, P. Y., & Handelsman, D. J. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_17 · Cited by 15
Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus
Strand, V. (1999) · Current Opinion in Rheumatology · doi:10.1097/00002281-199909000-00002 · Cited by 15
Novel approaches to therapy for systemic lupus erythematosus
Zandman‐Goddard, G., & Shoenfeld, Y. (2000) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(00)00074-1 · Cited by 15
Are alterations of lymphocyte subpopulations in polymicrobial sepsis and DHEA treatment mediated by the tumour necrosis factor (TNF)-αreceptor (TNF-RI)? A study in TNF-RI (TNF-RI–/–) knock-out rodents
Hildebrand, F., Pape, H., Harwood, P. J., Wittwer, T., Krettek, C., & van Griensven, M. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02598.x · Cited by 14
Fatigue in patients with systemic lupus erythematosus: the role of dehydroepiandrosterone sulphate
Overman, C., Hartkamp, A., Bossema, E., Bijl, M., Godaert, G., Bijlsma, J., Derksen, R., & Geenen, R. (2012) · Lupus · doi:10.1177/0961203312459105 · Cited by 16
Gender and Age in Lupus
Lahita, R. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10023-3 · Cited by 14
Methodological issues of corticosteroid use in SLE clinical trials
Corzillius, M., & Bae, S.-C. (1999) · Lupus · doi:10.1191/096120399680411407 · Cited by 13
Dehydroepiandrosterone replacement therapy
Arlt, W. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000224811.39318.73 · Cited by 11
Dehydroepiandrosterone replacement therapy
Arlt, W., & Allolio, B. (2001) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200106000-00005 · Cited by 11
Sex Hormones and Immune Function
Lahita, R. G. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00052-6 · Cited by 10
Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus
Merrill, J. T. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.6.1017 · Cited by 10
Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases - substitutes of adrenal and sex hormones
Straub, R. H., Schölmerich, J., & Zietz, B. (2000) · Zeitschrift für Rheumatologie · doi:10.1007/s003930070004 · Cited by 10
Editorial
Lahita, R. G. (1997) · Lupus · doi:10.1177/096120339700600602 · Cited by 10
Dehydroepiandrosterone (DHEA) Supplementation in Rheumatic Diseases: A Systematic Review
Skare, T. L., Hauz, E., & de Carvalho, J. F. (2023) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.20230825.dd · Cited by 10
Dehydroepiandrosterone Supplements: Bringing Sense to Sensational Claims
Nippoldt, T. B. (1998) · Endocrine Practice · doi:10.4158/ep.4.2.106 · Cited by 9
Specialized Treatment Approaches and Niche Therapies for Lupus Subsets
Wallace, D. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1893-5.00051-0 · Cited by 9
Androgen therapy in non-gonadal disease
Handelsman, D. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.018 · Cited by 9
A History of Psycho-Neuro-Endocrine Immune Interactions in Rheumatic Diseases
Straub, R. H., & Cutolo, M. (2024) · NeuroImmunoModulation · doi:10.1159/000540959 · Cited by 12
Intranasal Administration of Adrenocorticotropin-(1-24) Stimulates Adrenocortical Hormone Secretion
Hiroi, N., Ichijo, T., Ueshiba, H., & Miyachi, Y. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8399 · Cited by 7
Emerging drug therapies for systemic lupus erythematosus
Mok, C. C. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.597 · Cited by 7
Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect
Pagnoux, C., Dechartres, A., Giraudeau, B., Séror, R., Guillevin, L., & Ravaud, P. (2010) · Arthritis Care & Research · doi:10.1002/acr.20139 · Cited by 7
Systemic Lupus Erythematosus
Schiffenbauer, J., Chakravarty, E. F., & Strand, V. (2003) · Wiley eBooks · doi:10.1002/9781444315844.ch6 · Cited by 7
Pediatric lupus versus adult lupus role of the laboratory
Klein‐Gitelman, M. S. (2004) · Clinical and Applied Immunology Reviews · doi:10.1016/j.cair.2004.04.001 · Cited by 6
Treatment options for severe lupus nephritis.
Lenz, O., & Contreras, G. N. (2004) · PubMed · Cited by 6
Actualités et perspectives thérapeutiques du lupus systémique
Sibilia, J., & Pasquali, J. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2007.11.011 · Cited by 6
DHEA : célèbre et méconnue
Schlienger, J.-L., Perrin, A., & Goichot, B. (2002) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(02)00591-x · Cited by 6
Evaluation of Sex Hormone Levels in Patients with Pemphigus Vulgaris in Comparison to the Healthy Population
Lavaee, F., Rezazadeh, F., Saki, N., Tavazo, Z., & Baghaei, S. (2021) · BioMed Research International · doi:10.1155/2021/9947706 · Cited by 5
Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes
Skoglund, O., Walhelm, T., Thyberg, I. S. M., Eriksson, P., & Sjöwall, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185300 · Cited by 5
Pharmacokinetic and Pharmacodynamic Interactions between Dehydroepiandrosterone and Prednisolone in the Rat
Meno‐Tetang, G. M. L., Hon, Y. Y., Wart, S. V., & Jusko, W. J. (1999) · Drug metabolism and drug interactions · doi:10.1515/dmdi.1999.15.1.51 · Cited by 5
Effects of a coping intervention on patients with rheumatic diseases: Results of a randomized controlled trial
Savelkoul, M., de Witte, L., Candel, M. J. J. M., van der Tempel, H., & van den Borne, B. H. P. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200102)45:1 · Cited by 37
Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus
Furie, R. A. (2000) · Current Rheumatology Reports · doi:10.1007/s11926-996-0068-5 · Cited by 4
Evaluation of recent clinical trials in lupus
Brooks, E. B., & Liang, M. H. (1999) · Current Opinion in Rheumatology · doi:10.1097/00002281-199909000-00003 · Cited by 5
Prasterone
Kocis, P. T. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060100 · Cited by 5
Management of systemic lupus erythematosus in Chinese patients
Mok, C. C. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.6.925 · Cited by 4
Dehydroepiandrosterone and Melatonin: Two Neurohormones
Caley, C. F. (1999) · Journal of Pharmacy Practice · doi:10.1177/089719009901200312 · Cited by 4
Dehydroepiandrosterone (DHEA)
Mischley, L. K., Nicolai, P. J., & Gaby, A. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00085-7 · Cited by 4
Lupus nephritis: a review of the current pharmacological treatments
Mercadal, L., & Deray, G. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2263 · Cited by 4
Non-Herbal Nutritional Supplements—The Next Wave: A Comprehensive Review of Risks and Benefits for the C-L Psychiatrist
Crone, C. C., Gabriel, G., & Wise, T. N. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.4.285 · Cited by 4
Dehydroepiandrosterone and Pregnenolone
Sih, R., Kamel, H. K., Horani, M. H., & Morley, J. E. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-700-0_15 · Cited by 3
Pathogenesis of SLE: implications for rational therapy
Franchin, G., Peeva, E., & Diamond, B. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.11.009 · Cited by 3
Rheumatoide Arthritis - pathogenetische Bedeutung der neuroendokrinen Achsen und des peripheren Nervensystems
Härle, P., Cutolo, M., Schölmerich, J., & Straub, R. H. (2002) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-002-1216-y · Cited by 3
Adrenal Disorders in Rheumatology
Ormseth, M. J., & Sergent, J. S. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.09.005 · Cited by 3
Dehydroepiandrosterone and Pregnenolone
Tariq, S. H., Kamel, H. K., & Morley, J. E. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-375-0_18 · Cited by 3
New Trends in Topical and Systemic Immunosuppressive Treatment
Schneider, M., Fischer‐Betz, R., Gensch, K., Iking‐Konert, C., & Kuhn, A. (2006) · Technical report · doi:10.1016/s1571-5078(05)05023-3 · Cited by 3
Dehydroepiandrosterone (DHEA) for serious disease, a possibility?
Lahita, R. G. (1999) · Lupus · doi:10.1191/096120399678847722 · Cited by 3
Therapeutic advances in systemic lupus erythematosus
Mok, C. C. (2006) · APLAR Journal of Rheumatology · doi:10.1111/j.1479-8077.2006.00160.x · Cited by 2
Dehydroepiandrosterone (DHEA) in Aging, Disease Modification, and Symptom Control
Shane‐McWhorter, L. (1998) · Journal of Pharmaceutical Care in Pain & Symptom Control · doi:10.1300/j088v06n02_02 · Cited by 2
DHEA as a Putative Replacement Therapy in the Elderly
WATSON, R. R. (2011) · CRC Press eBooks · doi:10.1201/b11019-7 · Cited by 2
Traitements hormonaux et protection ovarienne au cours du lupus systémique
André, G. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2004.12.011 · Cited by 2
Dehydroepiandrosterone (DHEA) (Prasterone)
Pope, J. E., Cupp, M. J., & Tracy, T. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-303-3_8 · Cited by 1
Stressful Cognitive Dysfunction and the Immune System
Pukhalsky, A. L., Шмарина, Г. В., & Aleshkin, V. A. (2012) · Advances in Neuroimmune Biology · doi:10.3233/nib-012913 · Cited by 1
Tratamiento hormonal en las enfermedades reumáticas autoinmunitarias
Jara-Quezada, L. J., Mora-Trujillo, C. S., Lastra, O. L. V., & Saavedra-Salinas, M. A. (2005) · Reumatología Clínica · doi:10.1016/s1699-258x(05)72774-1 · Cited by 1
SYSTEMIC LUPUS ERYTHEMATOSUS 710.1
Barkhuizen, A., & Rosenbaum, J. T. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-2447-7.50102-x · Cited by 1
Sex bias in SLE
Lahita, R. G., Liang, Y., & McCoy, S. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00001-4 · Cited by 1
UNPROVEN AND EXPERIMENTAL THERAPIES
van Vollenhoven, R. (2004) · Elsevier eBooks · doi:10.1016/b978-012433901-9/50051-x · Cited by 1
Dehydroepiandrosterone versus placebo for Sjögren's syndrome: Comment on the article by Pillemer et al
van Vollenhoven, R. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21313 · Cited by 1
DHEA supplementation of systemic glucocorticoids for treatment of poison ivy dermatitis
Geracioti, T. D. (2005) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2005.02579.x · Cited by 1
B cell depletion in Systemic Lupus Erythematosus
Jonsdottir, T. (2009) · Cited by 1
Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases
Ramos‐Casals, M., Brito‐Zerón, P., Espinosa, G., & Cervera, R. (2008) · Technical report · doi:10.1016/s1571-5078(07)00209-7
Ätiopathogenese des systemischen Lupus erythematodes (SLE)
i, M. H., Voll, R. E., Gaipl, U. S., Kolowos, W., & Kalden, J. R. (2003) · Springer eBooks · doi:10.1007/978-3-642-55803-0_11
Modulation der Glucocorticoidwirkung durch Vitamin B6 und Dehydroepiandrosteron (DHEA) in menschlichen Immunzellen
Ellebrecht, I. (2005)
Le traitement du lupus érythémateux systémique en 2006
Sibilia, J. (2006) · Revue du Rhumatisme · doi:10.1016/j.rhum.2006.09.003
Activation of Hypothalamic Pituitary Axis in Critically Ill Patients
Baba, K. E., Zantout, M., & Azar, S. (2009) · The Endocrinologist · doi:10.1097/ten.0b013e318198b413
Early stopping of clinical trials in lupus and other uncommon rheumatologic diseases
LaValley, M. P., & Felson, D. T. (1999) · Lupus · doi:10.1191/096120399680411380
Sex Hormone Metabolism, Immune Function, and the Effect of Sex Hormones on Various Rheumatic Diseases
Lahita, R. G. (2004) · Principles of Gender-Specific Medicine · doi:10.1016/b978-012440905-7/50376-5
Pediatric lupus: Similarities and differences from adult onset lupus
Klein‐Gitelman, M. (1998) · Clinical Immunology Newsletter · doi:10.1016/s0197-1859(00)89059-7
Effects of the neuroendocrine system on development and function of the immune system
Cutolo, M., & Straub, R. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00025-5
DHEA as a Putative Replacement Therapy in the Elderly
Genazzani, A. D., & Lanzoni, C. (2011) · CRC Press eBooks · doi:10.1201/b11019-4
The role of DHEA in the aetiology of modern chronic disease
Powrie, Y. S. L. (2020) · SUNScholar (Stellenbosch University)
Immune System
Cimoch, P. J., Allen-Evenson, S., Place, J., Grotto, D., & Silverman, E. (2006) · CRC Press eBooks · doi:10.1201/9781420003413.ch15
Effects of the neuroendocrine system on development and function of the immune system
Cutolo, M., & Straub, R. H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00024-5
Rheumatoid Arthritis
Yasuda, G. T., Bongiorno, P. B., & Murray, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00205-4
Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action
Rogler, G. (2003) · Springer eBooks · doi:10.1007/978-1-4020-3477-0_26
Dehydroepiandrosterone (DHEA)
Szybala, C., Szybala, M. P., Mischley, L. K., Nicolai, P., & Gaby, A. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00074-1
Future directions
Furie, R. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00074-5
Treatment of Systemic Lupus Erythematosus
Schur, P. H., & Kammer, G. M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-239-5_18
Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action
Rogler, G. (2007) · Springer eBooks · doi:10.1007/0-387-25808-6_26
The Significance of Dehydroepiandrosterone for Fatigue in primary Sjögren’s Syndrome and Systemic Lupus Erythematosus
Hartkamp, A. (2014) · Utrecht University Repository (Utrecht University)
Administration de DHEA chez le sujet jeune et sain : effets sur les performances sportives, la composition corporelle et les réponses hormonales
Gravisse, N. (2018) · theses.fr (ABES) · doi:10.70675/22336bb9zed60z437fz9d15z68385c5831fa
Nutritional Supplementation in Systemic Lupus Erythematosus
Sule, S., & Petri, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-403-2_9
Sex, Pregnancy, and Autoimmunity
Lahita, R. G. (2006) · Elsevier eBooks · doi:10.1016/b978-012595961-2/50028-7
Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: Viewpoint based on a systemic pathogenetic role
Straub, R. H., & Cutolo, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3

Authors: Van Vollenhoven, R. F., Engleman, E. G., & Mcguire, J. L.
Affiliations: Stanford Medicine (US)
ORCID: Engleman, Edgar G.
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 1995-12
Volume: 38
Issue: 12
Pages: 1826-1831
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.1780381216
OpenAlex: W2070207717
Cited by: 192
References: 36
Citations by year: 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2018: 3 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 3 · 2012: 5
FWCI: 5.90
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3661 d)
Locations: Arthritis & Rheumatism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords: dehydroepiandrosterone, systemic lupus erythematosus, lupus flares, corticosteroid tapering, prednisone, SLEDAI, disease activity, acne, steroid-sparing therapy
MeSH terms: Adult, Dehydroepiandrosterone, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Lupus Erythematosus, Systemic, Prednisone, Severity of Illness Index, Chi-Square Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dehydroepiandrosterone in systemic lupus erythematosus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks